Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
The pharma industry has suffered a definitive loss in its legal battle against Medicare negotiations.
The Fifth Circuit Court of Appeals on Wednesday
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
PhRMA's Medicare price negotiation suit rebuffed in latest blow to industry IRA challenge
Merck, AZ lawsuits against Medicare price negotiations swatted down
Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program - Merck & Co (NYSE:MRK)
ACR: CMS rule on Medicare drug price negotiation could have ‘unintended consequences’
In the latest in a string of setbacks in biopharma’s efforts to fight Medicare drug price negotiations, a lawsuit from the…
The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The…
The rejection may make the pharma firms remaining lawsuits more difficult.
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue…
DC judge rejects Merck's challenge to Medicare drug price negotiations, ruling participation is
Pharmaceutical companies are trying to prevent Medicare from negotiating discounts for drugs. Their legal challenges have been…
